Erasca (ERAS)
(Delayed Data from NSDQ)
$1.50 USD
+0.10 (7.14%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $1.51 +0.01 (0.67%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ERAS 1.50 +0.10(7.14%)
Will ERAS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ERAS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ERAS
VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%
Merck Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '25 View
ERAS: What are Zacks experts saying now?
Zacks Private Portfolio Services
PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor
Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
Other News for ERAS
Erasca Confirms Directors and Ratifies KPMG Appointment
Erasca (ERAS) Gains FDA Clearance for Innovative KRAS Inhibitor | ERAS Stock News
Erasca announces IND clearance for ERAS-4001
Erasca announces IND clearance for ERAS-4001
Erasca GAAP EPS of -$0.11